product summary
Loading...
company name :
R&D Systems
product type :
antibody
product name :
Human/Primate CXCL1/GRO alpha /KC/CINC-1 Antibody
catalog :
MAB275-100
quantity :
100 ug (also 25 ug, 500 ug)
price :
529 USD
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
20326
reactivity :
human
application :
western blot, ELISA, immunohistochemistry, immunocytochemistry, neutralization, flow cytometry, immunohistochemistry - paraffin section
more info or order :
R&D Systems product webpage
citations: 24
Reference
Kahm Y, Kim I, Kim R. RanBP1: A Potential Therapeutic Target for Cancer Stem Cells in Lung Cancer and Glioma. Int J Mol Sci. 2023;24: pubmed publisher
Peng N, Kang H, Feng Y, Minikes A, Jiang X. Autophagy inhibition signals through senescence to promote tumor suppression. Autophagy. 2022;:1-17 pubmed publisher
Cornelison R, Yuan J, Tate K, Petrosky A, Beeghly G, Bloomfield M, et al. A patient-designed tissue-engineered model of the infiltrative glioblastoma microenvironment. NPJ Precis Oncol. 2022;6:54 pubmed publisher
Zhu Y, Prata L, Gerdes E, Netto J, Pirtskhalava T, Giorgadze N, et al. Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans. EBioMedicine. 2022;77:103912 pubmed publisher
Freitag N, Baston Buest D, Kruessel J, Markert U, Fehm T, Bielfeld A. Eutopic endometrial immune profile of infertility-patients with and without endometriosis. J Reprod Immunol. 2022;150:103489 pubmed publisher
Somerville T, Biffi G, Da ler Plenker J, Hur S, He X, Vance K, et al. Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation. elife. 2020;9: pubmed publisher
Flaherty E, Zhu S, Barretto N, Cheng E, Deans P, Fernando M, et al. Neuronal impact of patient-specific aberrant NRXN1α splicing. Nat Genet. 2019;51:1679-1690 pubmed publisher
Ashander L, Lie S, Ma Y, Rochet E, Washington J, Furtado J, et al. Neutrophil Activities in Human Ocular Toxoplasmosis: An In Vitro Study With Human Cells. Invest Ophthalmol Vis Sci. 2019;60:4652-4660 pubmed publisher
Fong L, Hotson A, Powderly J, Sznol M, Heist R, Choueiri T, et al. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discov. 2020;10:40-53 pubmed publisher
Logue S, McGrath E, Cleary P, Greene S, Mnich K, Almanza A, et al. Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy. Nat Commun. 2018;9:3267 pubmed publisher
Kitawaki Y, Nakamura Y, Kubota Nakayama F, Yamazaki Y, Miki Y, Hata S, et al. Tumor microenvironment in functional adrenocortical adenomas: immune cell infiltration in cortisol-producing adrenocortical adenoma. Hum Pathol. 2018;77:88-97 pubmed publisher
Kim E, Moon S, Kim D, Zhang X, Kim J. CXCL1 induces senescence of cancer-associated fibroblasts via autocrine loops in oral squamous cell carcinoma. PLoS ONE. 2018;13:e0188847 pubmed publisher
Henry C, Martin S. Caspase-8 Acts in a Non-enzymatic Role as a Scaffold for Assembly of a Pro-inflammatory "FADDosome" Complex upon TRAIL Stimulation. Mol Cell. 2017;65:715-729.e5 pubmed publisher
Chan T, Hsu C, Pai V, Liao W, Huang S, Tan K, et al. Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells. J Exp Med. 2016;213:2967-2988 pubmed
Ulland T, Jain N, Hornick E, Elliott E, Clay G, Sadler J, et al. Nlrp12 mutation causes C57BL/6J strain-specific defect in neutrophil recruitment. Nat Commun. 2016;7:13180 pubmed publisher
Xiang Z, Jiang D, Xia G, Wei Z, Chen W, He Y, et al. CXCL1 expression is correlated with Snail expression and affects the prognosis of patients with gastric cancer. Oncol Lett. 2015;10:2458-2464 pubmed
Salo S, Bitu C, Merkku K, Nyberg P, Bello I, Vuoristo J, et al. Human bone marrow mesenchymal stem cells induce collagen production and tongue cancer invasion. PLoS ONE. 2013;8:e77692 pubmed publisher
Gelderblom M, Weymar A, Bernreuther C, Velden J, Arunachalam P, Steinbach K, et al. Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke. Blood. 2012;120:3793-802 pubmed publisher
Hol J, Otterdal K, Breland U, Stang E, Pedersen T, Hagelsteen K, et al. Statins affect the presentation of endothelial chemokines by targeting to multivesicular bodies. PLoS ONE. 2012;7:e40673 pubmed publisher
Oladipo O, Conlon S, O Grady A, Purcell C, Wilson C, Maxwell P, et al. The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue. Br J Cancer. 2011;104:480-7 pubmed publisher
Meen A, Øynebråten I, Reine T, Duelli A, Svennevig K, Pejler G, et al. Serglycin is a major proteoglycan in polarized human endothelial cells and is implicated in the secretion of the chemokine GROalpha/CXCL1. J Biol Chem. 2011;286:2636-47 pubmed publisher
Kitaya K, Yasuo T. Aberrant expression of selectin E, CXCL1, and CXCL13 in chronic endometritis. Mod Pathol. 2010;23:1136-46 pubmed publisher
Moscova M, Marsh D, Baxter R. Protein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines. Cancer Res. 2006;66:1376-83 pubmed
Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol. 2005;175:6177-89 pubmed
product information
master code :
MAB275
SKU :
MAB275-100
product name :
Human/Primate CXCL1/GRO alpha /KC/CINC-1 Antibody
unit size :
100 ug (also 25 ug, 500 ug)
description :
The Human/Primate CXCL1/GRO alpha /KC/CINC-1 Antibody from R&D Systems is a mouse monoclonal antibody to CXCL1/GRO alpha/KC/CINC-1. This antibody reacts with human,primate,transgenic mouse. The Human/Primate CXCL1/GRO alpha /KC/CINC-1 Antibody has been validated for the following applications: Neutralization,Immunodepletion,Flow Cytometry,Western Blot,Immunohistochemistry,Immunohistochemistry-Paraffin,Immunocytochemistry,ELISA Capture (Matched Antibody Pair),Intracellular Staining by Flow Cytometry,CyTOF-ready.
target :
CXCL1/GRO alpha/KC/CINC-1
category :
Primary Antibodies
buffer :
Lyophilized from a 0.2 ╡m filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 ╡m filtered solution in PBS.
clonality :
Monoclonal
clone :
20326
conjugate :
Unconjugated
host :
Mouse
immunogen :
E. coli -derived recombinant human CXCL1/GRO alpha /KC/CINC-1
isotype :
IgG2b
purity :
Protein A or G purified from hybridoma culture supernatant
species :
Human,Primate,Transgenic Mouse
specificity :
Detects human CXCL1/GRO alpha /KC/CINC-1 in ELISAs and Western blots. In Western blots, this antibody shows approximately 20% cross-reactivity with recombinant human (rh) CXCL2/GRO▀ and rhCXCL3/GRO gamma and no cross-reactivity with recombinant rat (rr)CINC-1, rrCINC-2 alpha , rrCINC-2▀, rrCINC-3, rhMIP-1 alpha , recombinant mouse (rm)MIP-1 alpha , rmMIP-1▀, rmMIP-1▀, rhMIP-1 delta , rmMIP-1 gamma , rmMIP-2, rhMIP-3 alpha , rmMIP-3 alpha , rrMIP-3 alpha , rhMIP-3▀, or rmMIP-3▀.
gene symbol :
CXCL1
endotoxin note :
<0.10 EU per 1 ╡g of the antibody by the LAL method.
top caption :
Detection of CXCL1/GROa/KC/CINC-1 antibody in Human PBMCs Treated with LPS and Monensin antibody by Flow Cytometry.
applications :
Neutralization,Immunodepletion,Flow Cytometry,Western Blot,Immunohistochemistry,Immunohistochemistry-Paraffin,Immunocytochemistry,ELISA Capture (Matched Antibody Pair),Intracellular Staining by Flow Cytometry,CyTOF-ready
USD :
529 USD
alt names :
CINC1, CINC-1, FSP, GRO alpha, GRO1, GROa, KC, MGSA, MGSA-a, MGSA-alpha, NAP-3, SCYB1
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 6 months, -20 to -70 ░C under sterile conditions after reconstitution.
more info or order :
R&D Systems product webpage
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.